Physician profile
Shivani S Kamat
NPI 1326368549
$163,651.20
in general payments reported to CMS, 2019-2025
14 companies · $91K in 2025
The $91K reported for 2025 was more than what 98% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $649 · 2021: $226 · 2022: $7,162 · 2023: $30K · 2024: $35K · 2025: $91K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $107K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Travel and Lodging: $9,201 · Food and Beverage: $8,311 · Honoraria: $3,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $107,179.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,100.00 |
| Travel and Lodging | $9,201.16 |
| Food and Beverage | $8,310.63 |
| Honoraria | $3,700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $67,950.05 | 2022-2025 | |
| Glaukos Corporation | $35,665.05 | 2022-2025 | Travoprost Intraocular Implant - Idose, Idose, Idosetr |
| Nova Eye, INC. | $19,387.76 | 2023-2025 | |
| Alcon Vision LLC | $15,398.96 | 2022-2025 | Hydrus Microstent, Rocklatan, Acrysof Iq Panoptix Uv Iol |
| Bausch & Lomb Americas INC. | $11,626.03 | 2022-2025 | Vyzulta, Amvisc, Miebo |
| Alcon Research LLC | $7,240.00 | 2023-2025 | Rhopressa, Rocklatan |
| New World Medical,INC. | $5,088.71 | 2022-2025 | Streamline, Kahook Dual Blade, Clearpath |
| Aerie Pharmaceuticals, INC. | $692.82 | 2020-2021 | |
| Allergan, INC. | $366.15 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $128.39 | 2021-2025 | Tecnis Iol, Tecnis Simplicity, Veritas Vision System |
| Sight Sciences, INC. | $32.33 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Dompe US, INC. | $30.86 | 2024 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.31 | 2021 | |
| Ocular Therapeutix, INC. | $20.78 | 2024 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivani Kamat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.